RT Journal Article
SR Electronic
T1 Pathogenic <em>SPTBN1</em> variants cause a novel autosomal dominant neurodevelopmental syndrome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.31.20184481
DO 10.1101/2020.08.31.20184481
A1 Cousin, Margot A.
A1 Breau, Keith A.
A1 Creighton, Blake A.
A1 Spillmann, Rebecca C.
A1 Torti, Erin
A1 Dontu, Sruthi
A1 Tripathi, Swarnendu
A1 Ajit, Deepa
A1 Harper, Kathryn M.
A1 Stankewich, Michael C.
A1 Person, Richard E.
A1 Si, Yue
A1 Normand, Elizabeth A.
A1 Blevins, Amy
A1 May, Alison S.
A1 Bier, Louise
A1 Aggarwal, Vimla
A1 Mancini, Grazia M. S.
A1 van Slegtenhorst, Marjon A.
A1 Cremer, Kirsten
A1 Becker, Jessica
A1 Engels, Hartmut
A1 Aretz, Stefan
A1 MacKenzie, Jennifer J.
A1 Brilstra, Eva
A1 van Gassen, Koen L. I.
A1 van Jaarsveld, Richard H.
A1 Oegema, Renske
A1 Parsons, Gretchen M.
A1 Mark, Paul
A1 Helbig, Ingo
A1 McKeown, Sarah E.
A1 Stratton, Robert
A1 Cogne, Benjamin
A1 Isidor, Bertrand
A1 Cacheiro, Pilar
A1 Smedley, Damian
A1 Firth, Helen V.
A1 Bierhals, Tatjana
A1 Kloth, Katja
A1 Weiss, Deike
A1 Fairley, Cecilia
A1 Shieh, Joseph T.
A1 Kritzer, Amy
A1 Jayakar, Parul
A1 Kurtz-Nelson, Evangeline
A1 Bernier, Raphael
A1 Wang, Tianyun
A1 Eichler, Evan E.
A1 van de Laar, Ingrid M.B.H.
A1 McConkie-Rosell, Allyn
A1 McDonald, Marie
A1 Kemppainen, Jennifer
A1 Lanpher, Brendan C.
A1 Schultz-Rogers, Laura E.
A1 Gunderson, Lauren B.
A1 Pichurin, Pavel N.
A1 Yoon, Grace
A1 Zech, Michael
A1 Jech, Robert
A1 Winkelmann, Juliane
A1 ,
A1 ,
A1 Zimmermann, Michael T.
A1 Temple, Brenda
A1 Moy, Sheryl S.
A1 Klee, Eric W.
A1 Tan, Queenie K.-G.
A1 Lorenzo, Damaris N.
YR 2020
UL http://medrxiv.org/content/early/2020/09/02/2020.08.31.20184481.abstract
AB SPTBN1 encodes βII-spectrin, the ubiquitously expressed member of the β-spectrin family that forms micrometer-scale networks associated with plasma membranes. βII-spectrin is abundantly expressed in the brain, where it is essential for neuronal development and connectivity. Mice deficient in neuronal βII-spectrin expression have defects in cortical organization, global developmental delay, dysmorphisms, and behavioral deficiencies of corresponding severity. These phenotypes, while less severe, are observed in haploinsufficient animals, suggesting that individuals carrying heterozygous variants in this gene may also present with measurable compromise of neural development and function. Here we report the identification of heterozygous SPTBN1 variants in 29 individuals who present with global developmental, language and motor delays, mild to severe intellectual disability, autistic features, seizures, behavioral and movement abnormalities, hypotonia, and variable dysmorphic facial features. We show that these SPTBN1 variants lead to loss-of-function, gain-of-function, and dominant negative effects that affect protein stability, disrupt binding to key protein partners, and disturb cytoskeleton organization and dynamics. Our studies define the genetic basis of this new neurodevelopmental syndrome, expand the set of spectrinopathies affecting the brain and neural development, and underscore the critical role of βII-spectrin in the central nervous system.Competing Interest StatementE.T., R. E.P., Y.S., E.A.N., and A.B. are employees of GeneDx, Inc. The authors declare no other competing interests.Funding StatementM.A.C, L.E.S-R., and E.W.K. were supported by the Center for Individualized Medicine at Mayo Clinic. D.N.L. was supported by the University of North Carolina at Chapel Hill (UNC-CH) School of Medicine as a Simmons Scholar, by the National Ataxia Foundation, and by the US National Institutes of Health (NIH) grant R01NS110810. Microscopy was performed at the UNC-CH Neuroscience Microscopy Core Facility, supported, in part, by funding from the NIH-NINDS Neuroscience Center Grant P30 NS045892 and the NIH-NICHD Intellectual and Developmental Disabilities Research Center Support Grant U54 HD079124, which also supported, in part, the behavioral studies. Research reported in this manuscript was supported by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under Award Number U01HG007672 (Duke University to Dr. Vandana Shashi). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patient consent for participation and phenotyping was obtained through the referring clinical teams. Referring clinicians were requested to complete a comprehensive questionnaire that was based upon our current understanding of the phenotypic associations of SPTBN1. They included sections related to neurodevelopmental screening, behavior, dysmorphology, muscular, cardiac, and other systemic phenotypic features. Consent and collection of information conformed to the recognized standards of the Declaration of Helsinki and approved by the local institutional review boards (IRB), including the Mayo Clinic (IRB 12-009346), the Institute for Genomic Medicine at Columbia University (protocol AAAO8410) and the Ethics Committee of the Medical Faculty of the University of Bonn (approvals 131/08 and 024/12).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll original data files are available upon request